Semanteon Capital Management LP Buys New Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Semanteon Capital Management LP purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,609 shares of the biopharmaceutical company’s stock, valued at approximately $308,000.

Several other institutional investors and hedge funds have also bought and sold shares of ALNY. Quent Capital LLC boosted its holdings in Alnylam Pharmaceuticals by 246.0% in the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares during the last quarter. Anchor Investment Management LLC acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $38,000. GAMMA Investing LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $52,000. Lindbrook Capital LLC boosted its holdings in Alnylam Pharmaceuticals by 37.2% during the fourth quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock worth $71,000 after buying an additional 100 shares in the last quarter. Finally, Acadian Asset Management LLC grew its position in Alnylam Pharmaceuticals by 52.4% during the third quarter. Acadian Asset Management LLC now owns 904 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 311 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ALNY. Wolfe Research initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 15th. They set a “peer perform” rating on the stock. BMO Capital Markets reaffirmed an “outperform” rating and set a $234.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 27th. Citigroup cut their target price on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating for the company in a research note on Friday, February 16th. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, April 8th. Finally, The Goldman Sachs Group downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $230.00 to $173.00 in a research note on Friday, February 16th. Eight investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $215.88.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $143.31 on Friday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $218.88. The company has a 50 day moving average price of $150.29 and a 200 day moving average price of $165.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to analysts’ expectations of $439.38 million. The company’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter last year, the business posted ($1.68) earnings per share. On average, equities analysts predict that Alnylam Pharmaceuticals, Inc. will post -4.46 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.